Manager TitleAgeSince
Chief Executive Officer 53 30/08/2022
Director of Finance/CFO 55 02/05/2023
Chief Tech/Sci/R&D Officer 51 -
Director TitleAgeSince
Director/Board Member 53 01/09/2015
Chairman 71 15/04/2021
Director/Board Member 59 15/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
+5.88%+8.00% - - 15.15L
+0.14%+0.21%+1.29%+20.75% 4.86TCr
+1.89%+5.08%+492.59%+629.24% 4.63TCr
+1.83%+2.75%+15.61%+91.22% 4.2TCr
-0.50%-1.56%+24.67%+12.17% 3.95TCr
-2.74%-7.13%+18.72%+49.04% 3.17TCr
-1.14%-2.51%+27.52%+136.42% 1.65TCr
+0.59%-2.25% - - 1.63TCr
-0.17%-0.09%+2.57%+29.35% 1.4TCr
-2.60%-1.00%+77.85%+40.37% 1.33TCr
Average +0.32%-0.96%+82.60%+126.07% 2.98TCr
Weighted average by Cap. +0.07%-0.43%+105.65%+155.60%
Logo Amniotics AB
Amniotics AB (publ) is a Sweden-based biotech company that develops cell therapy drugs based on mesenchymal stem cells from amniotic fluid in its in-house GMP licensed facility. Amniotics' own marker technology is used to identify and select stem cells for different tissue types; Lung (PulmoStem), Brain (CogniStem), Kidney (NephroStem), Skin (CutiStem). It allows for selecting the type of cell to be used for specific tissue. The company has developed a process - patented in all steps - which includes collection of amniotic fluid, with a medical device developed by Amniotics, followed by sorting and propagation of stem cells and packaging of product in ampoules in its own GMP facility. Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.
Employees
4
  1. Stock Market
  2. Stocks
  3. AMNI Stock